Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A

Haemophilia

Volumn 17, Issue 6, 2011, Pages 884-889

  Leissinger, C ^a   Cooper, D L ^b   Solem, C T ^c  

^a TULANE UNIVERSITY   (United States)

^b NOVO NORDISK INC   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Haemophilia; Inhibitors; Registry

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CAUCASIAN; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; DISEASE SEVERITY; ETHNICITY; FUNCTIONAL STATUS; GROUPS BY AGE; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; NEGRO; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; AGE; CHILD; DAILY LIFE ACTIVITY; ETHNOLOGY; HISPANIC; IMMUNOLOGY; MALE; PATHOPHYSIOLOGY; REGISTER;

BLOOD CLOTTING INHIBITOR;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEMOPHILIA A; HISPANIC AMERICANS; HUMANS; MALE; REGISTRIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84857936786     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02509.x     Document Type: Article

References (17)

1. DiMichele D. Inhibitors in Hemophilia: A Primer, Fourth Edn. Montreal, QC: World Federation of Hemophilia, 2008.
2. Kruse-Jarres R, Barnett B, Leissinger C. Immune tolerance induction for the eradication of inhibitors in patients with hemophilia A. Expert Opin Biol Ther 2008; 8: 1885-96.
3. Valentino LA, Hakobyan N, Enockson C. Blood-induced joint disease: the confluence of dysregulated oncogenes, inflammatory signals, and angiogenic cues. Semin Hematol 2008; 45: S50-S57.
4. Wallny T, Lahaye L, Brackmann HH, Hess L, Seuser A, Kraft CN. Clinical and radiographic scores in haemophilic arthropathies: how well do these correlate to subjective pain status and daily activities? Haemophilia 2002; 8: 802-8.
5. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
6. Leissinger CA. Prophylaxis in haemophilia patients with inhibitors. Haemophilia 2006; 12(Suppl. 6): 67-72; discussion -3.
7. Shapiro AD. Why is primary prophylaxis underutilized in the United States? Haemophilia 2003; 9: 670-2.
8. Butler RB, McClure W, Wulff K. Practice patterns in haemophilia A therapy - a survey of treatment centres in the United States. Haemophilia 2003; 9: 549-54.
9. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9(Suppl. 1): 19-26; discussion.
10. Molho P, Rolland N, Lebrun T et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat. haemophiles@cch.ap-hop-paris.fr. Haemophilia 2000; 6: 23-32.
11. Soucie JM, Cianfrini C, Janco RL et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103: 2467-73.
12. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
13. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
14. Dimichele DM, Hay CR. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006; 4: 2271-3.
15. Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) (RESIST EXP). Available at Accessed November 30, 2010.
16. Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive (RESIST NAIVE). Available at Accessed November 30, 2010.
17. American Thrombosis and Hemostatis Network. Project Portfolio. Available at Accessed November 30, 2010.